Newswise — Oak Brook, IL – The July special issue of SLAS Discovery, “Functional Genomics for Target Identification,” features ten articles focused on three strategic pillars that form the foundation of the functional genomics discipline.
Functional genomics screens allow researchers to systematically disrupt large numbers of genes or proteins in order to reveal cellular phenotypes that enable gene function. Recent research shows that functional genomics has great potential for both the dissection of molecular mechanisms of human diseases and the reduction of the very high attrition rate in the drug discovery process. The long-term success of functional genomics platforms in addressing these challenges will be driven by advancements in the three strategic pillars highlighted within this issue.
Special issue editors Davide Gianni, Ph.D., (AstraZeneca, United Kingdom) and Stuart Farrow, Ph.D., (CRUK Therapeutic Discovery Laboratories, United Kingdom) selected research reviews and articles that cover a variety of relevant topics, including:
- Secretome-Based Screening in Target Discovery
- The New Frontier of Functional Genomics: From Chromatin Architecture and Noncoding RNAs to Therapeutic Targets
- A Whole Genome-Wide Arrayed CRISPR Screen in Primary Organ Fibroblasts to Identify Regulators of Kidney Fibrosis
- Arrayed CRISPR Screening Identifies Novel Targets That Enhance the Productive Delivery of mRNA by MC3-Based Lipid Nanoparticles
- CRISPR Meets Zebrafish: Streamlining the Discovery of New Therapeutic Targets
- Combined siRNA and Small Molecule Phenotypic Screening Approach Identifies Targets Regulating Rhinovirus Replication in Human Bronchial Epithelial Cells
- Delivering Robust Candidates to the Drug Pipeline Through Computational Analysis of Arrayed CRISPR Screens
- Developing an Arrayed CRISPR-Cas9 Co-culture Screen for Immuno-oncology Target ID: The Importance of a ‘Natural’ System
- Combining Machine Learning and Exploratory Data Analysis Methods for Phenotypic Functional Genomics Screening
- A Novel End to End Workflow for the Dissection of Cellular Regulatory Networks of NF-κB Using Arrayed CRISPR gRNA Libraries
SLAS (Society for Laboratory Automation and Screening) is an international community of 16,000 professionals and students dedicated to life sciences discovery and technology. The SLAS mission is to bring together researchers in academia, industry and government to advance life sciences discovery and technology via education, knowledge exchange and global community building.
SLAS Discovery: Advancing the Science of Drug Discovery, 2018 Impact Factor 2.192. Editor-in-Chief Robert M. Campbell, Ph.D., Eli Lilly and Company, Indianapolis, IN (USA).
SLAS Technology: Translating Life Sciences Innovation, 2018 Impact Factor 2.048. Editor-in-Chief Edward Kai-Hua Chow, Ph.D., National University of Singapore (Singapore).